The oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors are potential alternatives to the ESA (erythropoietin-stimulating agents) approach for the treatment of anemia in patients with CKD. The gene discussed is EPO; the disease is anemia (phenotype).